Major trial tests new drug to stop breast Cancer's return
NCT ID NCT07349069
Summary
This large study is testing whether a new drug called HRS-8080 works better than standard hormone therapy at preventing breast cancer from returning. It involves 4,800 women with high-risk early breast cancer who have already completed 2-5 years of initial hormone treatment. The goal is to see if HRS-8080 can keep cancer away longer and improve survival compared to current standard care.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, 200032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The First Affiliated Hospital of Nanjing Medical University
RECRUITINGNanjing, Jiangsu, 210029, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.